美国眼科学会特别报告:羟氯喹视网膜病变筛查建议(2025年修订版)
美国眼科学会(AAO)发布2025年修订版羟氯喹视网膜病变筛查建议。推荐每日剂量≤5.0 mg/kg实际体重,严重肥胖者保持在400 mg/日以下。主要筛查工具为OCT和宽视野眼底自发荧光(FAF),视野(VF)和多焦视网膜电图(mfERG)为次要确认试验。建议用药后尽早基线和每年筛查,无显著风险因素者前5年可暂缓年度筛查。
要点
- 推荐每日剂量≤5.0 mg/kg实际体重,严重肥胖者保持在400 mg/日以下。
- 主要筛查工具为OCT和宽视野FAF,VF和mfERG为次要确认试验。
- 建议用药后尽早基线和每年OCT和FAF筛查,无显著风险因素者前5年可暂缓年度筛查。
核心结论
- 视网膜在羟氯喹(HCQ)治疗期间通常多年保持临床正常,但可能出现不可预测的毒性体征。
- 欧洲裔患者多数表现为旁中心凹型毒性,东亚裔患者倾向表现为中心旁型毒性,筛查应同时寻找两种模式。
- 轻度视网膜病变在停用HCQ后不太可能进展,但重度视网膜病变可能持续恶化多年。
- 早期识别毒性体征后,更需与患者及其医疗提供者沟通停用HCQ或继续谨慎监测的选项。
研究设计与样本
- 美国眼科学会(AAO)基于当前知识对羟氯喹视网膜病变筛查建议进行的修订报告。
主要发现
- 推荐每日剂量保持≤5.0 mg/kg实际体重不变,严重肥胖患者保持在400 mg/日以下。
- 除剂量和疗程外,合并肾脏疾病和他莫昔芬使用增加风险,较大年龄开始HCQ治疗也增加风险。
- 主要筛查工具应为OCT和宽视野FAF,VF和mfERG为次要确认试验。
- 较新的VF算法如24-2C可同时筛查旁中心凹和中心旁区域。
- 轻度视网膜病变在停用HCQ后不太可能进展,但重度视网膜病变可能持续恶化多年。
关键数值与推荐
- 推荐每日剂量≤5.0 mg/kg实际体重不变;严重肥胖患者保持在400 mg/日以下。
- 建议开始HCQ后尽早进行基线筛查检查,包括眼底、OCT和FAF,不仅排除既存病变,也用于与后续结果比较。
- 推荐使用HCQ期间每年进行OCT和FAF筛查,但若无显著风险因素,前5年可暂缓。
- 主要筛查工具应为OCT和宽视野FAF;VF和mfERG为次要确认试验。
临床怎么用
- 筛查检查应同时寻找旁中心凹型和中心旁型毒性模式。
- 开始HCQ后尽早进行基线筛查,包括眼底、OCT和FAF,用于排除既存病变并与后续结果比较。
- 使用HCQ期间推荐每年OCT和FAF筛查,无显著风险因素者前5年可暂缓年度筛查。
- 早期识别毒性体征后,需与患者及其医疗提供者沟通停用HCQ或继续谨慎监测的选项。
局限性
- 影像和人工智能分析用于HCQ筛查的实验性进展尚未经验证用于一般用途,目前也未广泛可用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The American Academy of Ophthalmology recommendations on screening for hydroxychloroquine (HCQ) retinopathy are now a decade old. This revision provides an update based on current knowledge. Major points and changes are as follows. NATURE OF TOXICITY: The retina typically remains clinically normal for many years on HCQ, but there is an unpredictable point at which signs of toxicity may develop. PATTERN OF TOXICITY: Most eyes of patients of European heritage have a parafoveal pattern of toxicity, whereas eyes of East Asian patients tend to present with pericentral toxicity, but there are many exceptions, and screening examinations should look for both patterns. DOSAGE: The recommended daily dosage remains unchanged at ≤5.0 mg/day/kg real weight. Keep under 400 mg/day for severely obese patients. RISK FACTORS: Beyond dose and duration, concurrent renal disease and tamoxifen use increase risk, as does initiation of HCQ therapy at an older age. CLINICAL TESTS: The primary screening tool should be OCT, along with wide-pattern fundus autofluorescence (FAF). Visual field (VF) and multifocal electroretinography (mfERG) are secondary confirmatory tests. Newer VF algorithms such as 24-2C can screen parafoveal and pericentral regions simultaneously. SCREENING: A baseline screening examination, including fundus, OCT, and FAF, is advised soon after HCQ is begun, not only to rule out preexisting conditions but also for comparison with later results. Annual screening with OCT and FAF is recommended while using HCQ, but may be deferred during the first 5 years if there are no significant risk factors. PROGRESSION: Mild retinopathy is unlikely to progress after discontinuation of HCQ, but severe retinopathy may continue to worsen for many years. IMPLICATIONS OF EARLY SIGNS OF TOXICITY: With earlier recognition comes greater need to communicate with patients and their medical providers regarding options to stop HCQ or continue with cautious monitoring. NEW TECHNOLOGY: There have been experimental advances in imaging and artificial intelligence analysis for HCQ screening, but none have been validated for general use or are widely available at this time. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
引用
- Marmor MF, Ahn SJ, Ehlers JP, et al. Special AAO Report: Recommendations on Screening for Hydroxychloroquine Retinopathy (2025 Revision). Ophthalmology. 2025. PMID: 41232611. doi:10.1016/j.ophtha.2025.11.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。